CD123-CD33 compound CAR-T cells

CD123-CD33 compound CAR-T cells (ICG-136) is an investigational, autologous, dual-targeting chimeric antigen receptor (CAR) T-cell therapy developed by iCell Gene Therapeutics. It is designed to simultaneously target CD123 (interleukin-3 receptor alpha chain) and CD33, which are highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSCs). By targeting both antigens, the therapy aims to prevent antigen-escape-mediated relapse, a common mechanism of resistance in single-target CAR-T therapies. The CAR-T cells are engineered using a lentiviral vector and also express CD52 on their surface, which serves as a safety switch allowing for rapid depletion of the cells using the anti-CD52 monoclonal antibody alemtuzumab in the event of severe toxicity. It is currently in Phase I clinical development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Other names

123b-33bcCAR T cells123b-33bcCAR-T cellsCD123-CD33 cCAR T cellsCD-123-CD33 cCAR T cellsCD 123-CD33 cCAR T cellsCD123-CD33 cCAR-T cellsCD-123-CD33 cCAR-T cellsCD 123-CD33 cCAR-T cellsCD123-CD33 compound CAR T cellsCD-123-CD33 compound CAR T cellsCD 123-CD33 compound CAR T cellsCD123/CD33-expressing compound CAR-T cells